KAI Pharmaceuticals to receive manufacturing services from Formatech

Nov 18 2009

Today, Formatech announced that they have selected KAI Pharmaceuticals, Inc. and their KAI-4169 compound as the second clinical candidate to receive Formatech’s manufacturing services under its Fillanthropy Program. KAI-4169 is being evaluated for use in the treatment of secondary hyperparathyroidism. Under the Fillanthropy Program, Formatech will donate the services required to aseptically fill and finish one lot of the drug product for use in support of KAI’s upcoming clinical trials.

Formatech plans to complete the production run of KAI-4169 in the first quarter of 2010. “We’re excited to have the opportunity to work with KAI on this program,” said Jeffrey Bernard, Formatech’s Director of Business Development. “KAI’s technology for developing selective Protein C Kinase inhibitors is very promising and has the potential to be very impactful in the treatment of a number of diseases. We’re pleased to donate our services for this program and we wish KAI success with this candidate.”

“It is an honor to receive this award from Formatech as part of their philanthropic effort,” said Steve James, President and Chief Executive Officer of KAI Pharmaceuticals. “We appreciate Formatech’s commitment to this program. Secondary hyperparathyroidism is leading cause of morbidity and mortality in patients with chronic kidney disease. This fill will help support our ‘4169 program and we look forward to exciting results in the year ahead.”